- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07942025
90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study
This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Zheyu Zhou
- Telefoonnummer: +86 18851092739
- E-mail: zzys02910@btch.edu.cn
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 102218
- Beijing Tsinghua Changgung Hospital
-
Contact:
- Lin Zhang
- Telefoonnummer: +86 15699793366
- E-mail: zla02285@btch.edu.cn
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400038
- Southwest Hospital, Army Medical University
-
Contact:
- Hui Zhang
- Telefoonnummer: +86 02368754000
- E-mail: 13637912611@163.com
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Mengchao Hepatobiliary Hospital of Fujian Medical University
-
Contact:
- Wuhua Guo
- Telefoonnummer: +86 059188110232
- E-mail: guowuhua@aliyun.com
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510630
- The First Affiliated Hospital of Jinan University
-
Contact:
- Chengzhi Li
- Telefoonnummer: +86 02038688888
- E-mail: lichengzhi@jnu.edu.cn
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- The First Hospital of China Medical University
-
Contact:
- Haibo Shao
- Telefoonnummer: +86 02483283333
- E-mail: haiboshao@aliyun.com
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Contact:
- Xin Zheng
- Telefoonnummer: +86 02985323112
- E-mail: xin.zheng.xjtu@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.
Beschrijving
Inclusion Criteria:
- Initially unresectable primary liver cancer.
- Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
- Postoperative histopathological examination confirmed HCC.
Exclusion Criteria:
- Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
- Presence of extrahepatic metastasis prior to curative-intent hepatectomy.
- Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
- Failure to achieve R0 resection.
- Incomplete clinical data.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: OTHER
Cohorten en interventies
Groep / Cohort |
|---|
|
90Y-SIRT-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
|
TACE-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Postoperative recurrence-free survival (RFS)
Tijdsspanne: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Postoperative overall survival (OS)
Tijdsspanne: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
|
|
Pathological complete response (pCR) rate
Tijdsspanne: Immediately after curative-intent hepatectomy.
|
pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Major pathological response (MPR) rate
Tijdsspanne: Immediately after curative-intent hepatectomy.
|
MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Microvascular invasion (MVI) positivity rate
Tijdsspanne: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Satellite nodule positivity rate
Tijdsspanne: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Postoperative complication rate
Tijdsspanne: Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria. |
Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
Andere uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Percentage change in tumor markers
Tijdsspanne: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
|
Percentage change in maximum tumor diameter
Tijdsspanne: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Lin Zhang, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- KX26-0904-0317
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .